HC Wainwright Has Positive Forecast for ANIX FY2025 Earnings

Key Points

• HC Wainwright has increased its FY2025 EPS estimates for Anixa Biosciences to ($0.35) per share, slightly up from a previous estimate of ($0.38), while maintaining a "Buy" rating with a price target of $7.00.
• The consensus estimate for Anixa Biosciences' full-year earnings stands at ($0.41) per share, indicating a potential upside compared to the increased estimates from analysts.
• Anixa's stock has a current average rating of "Buy" from multiple analysts, with a consensus price target of $9.00, reflecting positive sentiment towards the company's performance.

Anixa Biosciences Inc (NASDAQ:ANIX - Free Report) - Investment analysts at HC Wainwright boosted their FY2025 EPS estimates for Anixa Biosciences in a report issued on Thursday, September 11th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.35) per share for the year, up from their prior forecast of ($0.38). HC Wainwright has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for Anixa Biosciences' current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Anixa Biosciences' Q4 2025 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.38) EPS.

A number of other equities analysts have also recently commented on ANIX. D. Boral Capital reissued a "buy" rating and set a $10.00 price target on shares of Anixa Biosciences in a report on Tuesday, September 9th. Wall Street Zen raised Anixa Biosciences from a "sell" rating to a "hold" rating in a research note on Friday, June 6th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $9.00.

Anixa Biosciences Price Performance

Shares of ANIX opened at $2.93 on Monday. The firm has a 50 day simple moving average of $3.10 and a two-hundred day simple moving average of $2.97. Anixa Biosciences has a one year low of $2.07 and a one year high of $4.20. The company has a market cap of $96.46 million, a P/E ratio of -8.37 and a beta of 0.58.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its quarterly earnings results on Wednesday, September 10th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03.

Institutional Trading of Anixa Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of ANIX. Millennium Management LLC bought a new position in Anixa Biosciences during the 4th quarter worth $26,000. NewEdge Advisors LLC acquired a new stake in shares of Anixa Biosciences in the second quarter valued at about $33,000. Private Advisor Group LLC bought a new position in shares of Anixa Biosciences during the first quarter worth about $35,000. Benjamin Edwards Inc. acquired a new position in shares of Anixa Biosciences in the second quarter worth approximately $37,000. Finally, Marshall Wace LLP bought a new stake in Anixa Biosciences in the second quarter valued at approximately $39,000. 29.13% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Anixa Biosciences

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. purchased 10,000 shares of the company's stock in a transaction dated Thursday, July 31st. The stock was purchased at an average price of $3.08 per share, with a total value of $30,800.00. Following the completion of the purchase, the director owned 953,334 shares of the company's stock, valued at approximately $2,936,268.72. The trade was a 1.06% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. In the last ninety days, insiders have purchased 35,000 shares of company stock valued at $110,700. Corporate insiders own 25.30% of the company's stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.